Mineralys Therapeutics Inc. (MLYS) News
Filter MLYS News Items
MLYS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MLYS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MLYS News From Around the Web
Below are the latest news stories about MINERALYS THERAPEUTICS INC that investors may wish to consider to help them evaluate MLYS as an investment opportunity.
Mineralys Therapeutics Advances Lorundrostat to Phase 2 TrialsAn update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA has cleared their Investigational New Drug Application for a Phase 2 clinical trial of lorundrostat, aimed at treating moderate-to-severe obstructive sleep apnea (OSA) and hypertension. This trial is expected to begin in the first quarter of 2025 and represents an expansion of lorundrostat’s market potential into OSA, furthering Mineralys’ positioning in the treatment of al |
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive sleep apnea represents Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases – – Initiation of the trial anticipated in the first quarter of 2025 – RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeuti |
Mineralys Therapeutics Announces Q3 2024 Results and UpdatesMineralys Therapeutics, Inc. ( (MLYS) ) has released its Q3 earnings. Here is a breakdown of the information Mineralys Therapeutics, Inc. presented to its investors. Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing treatments for hypertension, chronic kidney disease, and related conditions driven by dysregulated aldosterone. In its third-quarter 2024 earnings report, Mineralys Therapeutics highlighted key advancements in its clinical trials and fi |
Q3 2024 Mineralys Therapeutics Inc Earnings CallQ3 2024 Mineralys Therapeutics Inc Earnings Call |
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biophar |
Mineralys Therapeutics to Participate in Upcoming Investor ConferencesRADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference:Date:Tuesday, November 12, 2024Time:4:00pm ESTFormat:Fireside ChatWeb |
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-912 |
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular dis |
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here. The event will feature comments |
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |